Alzheimer’s disease is a condition that strikes at the core of what it means to be human—our ability to think, remember, and connect with others. This progressive neurological disorder is the leading cause of dementia worldwide, affecting millions of individuals and families. Its defining features—amyloid plaques and tau tangles in the brain—were first identified over a century ago. Yet, the way we diagnose Alzheimer’s has remained remarkably static for much of that time, often relying on clinical symptoms that appear only after significant brain damage has occurred.
In 2024, a major shift in diagnostic criteria offers new hope and new challenges, rethinking how we identify and stage Alzheimer’s. This change promises earlier detection, but also raises important ethical and practical questions about what it means to diagnose a disease that may be present without symptoms.
How We Diagnosed Alzheimer’s Until Now
For decades, diagnosing Alzheimer’s was a process that started when someone—or their family—noticed memory loss or confusion interfering with daily life. A visit to a doctor might lead to a series of steps: ruling out conditions like vitamin deficiencies or depression, assessing cognitive function through neuropsychological testing, and using brain imaging or lab tests to search for signs of Alzheimer’s.
Neuropsychologists, specialists in understanding the brain’s impact on behavior, have long played a key role in this process. Through detailed cognitive testing, they can identify patterns of impairment often seen in Alzheimer’s:
- Memory Problems: Difficulty recalling recent events or learning new information, especially when compared to preserved older memories, is a hallmark of early Alzheimer’s.
- Language Issues: Trouble finding the right words or following complex conversations may arise.
- Executive Dysfunction: Challenges with planning, multitasking, or problem-solving are common.
- Spatial Disorientation: Getting lost in familiar places or struggling with visual-spatial tasks, like copying a simple drawing.
These tests don’t just reveal what’s wrong—they can also help rule out other conditions, like strokes or mental health disorders, that mimic Alzheimer’s. However, traditional methods often identified the disease at a moderate or late stage, after the damage was done.
What Changed in 2024?
The new diagnostic criteria, introduced by leading medical and neurological organizations, represent a shift toward biological evidence. Instead of waiting for symptoms to appear, doctors can now diagnose Alzheimer’s based on the presence of its biological markers:
- Amyloid and Tau Proteins: Detected through PET scans, cerebrospinal fluid tests, or even newer blood tests.
- Neurodegeneration: Evidence of brain shrinkage or other changes, visible in MRI scans or measurable through specific biomarkers.
The disease is now categorized as a continuum with three stages:
- Preclinical Alzheimer’s Disease: This stage is defined by biomarker evidence of Alzheimer’s in individuals who show no outward symptoms. It may last for years, even decades.
- Mild Cognitive Impairment (MCI) Due to Alzheimer’s: Subtle problems with memory or thinking appear, but people can still live independently and manage daily tasks.
- Alzheimer’s Dementia: This is the stage where cognitive decline significantly interferes with everyday life, from managing finances to recognizing loved ones.
This biomarker-based approach means Alzheimer’s can theoretically be diagnosed in people who feel perfectly healthy. The goal is to identify the disease earlier, when treatments are more likely to be effective—or, in the future, to intervene before symptoms ever develop.
The Role of Neuropsychology in a Changing Landscape
Even with these advancements, neuropsychologists remain an essential part of the diagnostic process. Biomarkers can tell us if someone has the pathology of Alzheimer’s, but they don’t reveal how that pathology is affecting a person’s daily life. Detailed cognitive testing helps bridge this gap, providing a nuanced picture of someone’s functioning.
For example, if a patient complains of memory problems, neuropsychologists can determine whether these issues are consistent with normal aging, an early stage of Alzheimer’s, or another condition entirely. Testing might reveal patterns like:
- Preserved Attention with Memory Deficits: A profile often seen in early Alzheimer’s.
- Patchy Deficits Across Cognitive Domains: Suggestive of vascular dementia or mixed pathologies.
- Worsening Cognitive Skills Over Time: Neuropsychologists often conduct repeat testing to track changes, offering a clearer picture of progression.
This information isn’t just helpful for diagnosis; it’s crucial for planning. Families can use the results to make decisions about care, work, and legal matters. It also helps patients access services and participate in clinical trials.
Why These Changes Are Controversial
The 2024 criteria have sparked excitement, but they’re not without controversy. Diagnosing Alzheimer’s in people without symptoms raises a host of ethical, emotional, and practical issues:
- Emotional Toll: How does it feel to know you have a disease that might not cause symptoms for years? For some, this knowledge provides clarity and time to prepare; for others, it may lead to anxiety or depression.
- Limited Interventions: While there are new treatments targeting amyloid and tau, their effectiveness is modest, and they work best early in the disease. For those diagnosed at the preclinical stage, the options may feel frustratingly limited.
- Resource Strain: Expanding the diagnostic pool could overwhelm healthcare systems. If millions of asymptomatic people are suddenly eligible for monitoring and care, how will we prioritize resources?
Looking Ahead with Hope and Purpose
What these changes make clear is that Alzheimer’s is no longer just an end-stage disease. It’s a continuum, starting long before symptoms appear. This reframing opens the door to earlier interventions and, perhaps one day, prevention. It also shifts the narrative around Alzheimer’s from one of inevitability to one of opportunity.
For neuropsychologists, neurologists, and other specialists, the new criteria are both a challenge and a call to action. Early detection demands greater collaboration between biomarker testing and cognitive assessment, ensuring that each person’s unique story is understood and addressed.